3 Reasons Not to Sleep on ResMed Stock

ResMed reported Q2 FY2026 revenue up 11% YoY (quarter ended Dec. 31, 2025) with operating income rising 18%, and the company has a market value near $38B. The stock trades at a forward P/E of ~22 versus a five-year average of 29 (price/sales ~7 vs 5-year avg 7.8), and the firm is investing in digital health and next‑gen devices (9M myAir users, claims 144M lives impacted). Risks include uncertain Medicare reimbursement and potential alternative treatments, but management expects continued investment to scale digital capabilities and sustain profitable growth.

Analysis

ResMed’s investment in connected devices and behaviorally‑driven software creates a classic network-effect lever: better adherence data should raise customer lifetime value by reducing churn and increasing consumable stickiness, which converts one‑time device sales into higher‑margin recurring revenue over 12–36 months. That dynamic also lengthens payor negotiation windows — as ResMed demonstrates measurable downstream health improvements, it gains leverage to push for bundled reimbursements or subscription-style contracts with providers.

Competitively, any operational or balance‑sheet stress at legacy incumbents removes friction for ResMed to accelerate share gains in hospital and homecare channels; the second‑order winners are precision sensor/compute providers that supply cloud/edge analytics for sleep devices, while commoditized mask suppliers face margin compression and higher volume. Conversely, the push to cloud connectivity materially increases cyber, privacy, and post‑market surveillance exposure — any large security incident or data‑privacy ruling could force expensive redesigns and slow adoption over quarters.

Key catalysts and risks are cadence‑specific: near term (days–weeks) watch guidance and incremental metrics on paid subscriptions and device attach; medium term (6–18 months) monitor Medicare reimbursement rulings and payor pilots that determine unit economics; long term (2–4 years) the tail risk is therapeutic substitution (implantable stimulators or pharmacologic advances) that can structurally reduce TAM. Given these tradeoffs, the valuation gap looks like a binary asymmetric bet: modest near‑term upside if execution stalls, but >20–30% upside if digital monetization and reimbursement wins materialize within 12–24 months.

Key Decisions for Investors

• Core long RMD (6–18 months): size a 3–5% portfolio position in shares or buy 9–15 month ITM calls (delta ~0.5–0.6) to capture digital monetization. Target +25–35% total return if subscription adoption accelerates; hard stop / hedge if quarterly digital ARPU growth misses guidance by >200bps.
• Relative pair (6–12 months): long RMD / short PHG equal notional. Rationale: accelerate share gains from incumbent disruption and weaker Philips fundamentals. Expect 15–30% relative outperformance; trim if PHG posts stronger than feared service recovery or legal resolution within 3 months.
• Volatility‑funded LEAP (12–24 months): buy RMD LEAP calls and sell near‑dated PHG calls to finance premium. This trade expresses conviction in RMD’s multi‑year digital LTV expansion while monetizing short‑term downside consensus on Philips. Plan for <25% premium financing cost; max loss = LEAP premium if thesis fails.
• Tactical hedge / satellite (3–12 months): buy modest NVDA single‑name exposure (calls or +1% weight) to play higher compute intensity in cloud/edge medical analytics. Reward is indirect and small vs core RMD exposure, downside is NVDA idiosyncratic risk — cap to 0.5–1% portfolio to avoid correlation blowups.